Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study

Introduction: While ample evidence on improved glycemic control, weight reduction, and lowered blood pressure (BP) with sodium-glucose cotransporter type 2 inhibitors (SGLT2is) exists, real-world data on the potential benefit of SGLT2i on the diabetic population in the Middle East are lacking. The a...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ahmed Hassoun, Denish Kumar Dhanwal, Jalal Nafach, Yasmin Ajaz, Asif Majid Khan, Abdullah Ben Nakhi, Monira AlArouj, Khadija Hafidh, Majdi AlNajjar, Ahmed Reyas, Sana Qamar, Mohamed Alsayed, Ahmad Bdair
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Knowledge E 2022-01-01
Sarja:	Dubai Diabetes and Endocrinology Journal
Aiheet:	dapagliflozin sodium-glucose cotransporter type 2 sodium-glucose cotransporter type 2 inhibitors diabetes mellitus type 2 diabetes mellitus type 2 diabetes
Linkit:	https://www.karger.com/Article/FullText/519871
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!